Emerging evidence indicates that germline variations may interact with somatic events in carcinogenesis. However, the germline-somatic interaction in lung cancer remains largely unknown. We investigated whether lung cancer driver genes (CDGs) were more likely to locate within cancer susceptibility regions. Pathway analysis was performed to identify common pathways underlying CDGs and cancer susceptibility genes (CSGs). Next, we analyzed the associations between lung cancer risk SNPs and somatic alterations, including mutations and copy number alterations, in the level of genes, pathways, and overall burden of alterations. Enrichment analysis showed that lung CDGs are more likely to locate within cancer susceptibility regions (p 5 8.40 3 10 23 ). Both of lung CSGs and CDGs showed significant enrichment in pathways such as cell cycle and p53 signaling pathway. Gene-based analysis showed that rs36600 (22q12.2) was associated with somatic mutations within ARID1A (OR 5 2.45, 95%CI: 1.47-4.08, p 5 5.78 3 10 24
Introduction
Inherited germline genetic variants and somatic alterations acquired during cell division are crucial in carcinogenesis, including lung. Germline variants determine the susceptibility to lung cancer for a specified individual. Over past few years, dozens of single nucleotide polymorphisms (SNPs) that are associated with lung cancer risk have been identified by genome wide association studies (GWAS). 1 However, somatic alterations confer a selective growth advantage for the cells and can lead to cancer even though the majority of somatic mutations are harmless. 2 For lung cancer, somatic mutations in TP53, RB1, CDKN2A and PIK3CA, as well as deletions in CDKN2A were identified in both lung adenocarcinoma (lung ADC) and lung squamous cell carcinoma (lung SqCC). [3] [4] [5] Cancer-related SNPs and somatic alterations are usually analyzed separately. However, their joint analysis could be more informative, as several lines of evidence reveal the interplay between genetic variants and somatic alterations on cancer development. Recently, it was reported that bladder cancer risk-related SNP rs17000526 in the APOBEC3 region could regulate the expression of APOBEC3B (a mutationcausing enzymes) and were additionally associated with elevated level of APOBEC-signature mutations. 6 Another study on Ewing sarcoma showed that a risk SNP near EGR2 could facilitate binding of WESR1-FLI1 chimeric oncoprotein to the EGR2 locus, leading to higher EGR2 expression and increased susceptibility to Ewing sarcoma. 7 In addition, Carter et al. analyzed genomic data of 5,954 tumors and identified 412 interactions between genetic variants and somatic alterations in specific cancer driver genes. 8 As for lung cancer, TERT polymorphism rs2736100 was associated with EGFR mutated non-small cell lung cancer (NSCLC), but not EGFR wide-type NSCLC. 9 And risk SNPs of lung ADC on 5p15.33, 6p21.3, 3q28 and 17q24.2 showed stronger effect on EGFR mutated lung ADC compared to EGFR wide-type lung ADC. 10 However, the relationships between risk SNPs and somatic alterations in lung cancer have not been systematically investigated.
In our study, we performed an enrichment analysis to investigate whether lung cancer driver genes (CDGs) are more likely to locate within cancer susceptibility regions, and whether lung cancer susceptibility genes (CSGs) and CDGs are involved in shared biological pathways. Next, we analyzed the associations between lung cancer risk SNPs and somatic alterations in the level of genes, pathways and overall burden of alterations (Fig. 1 ).
Materials and Methods

Lung cancer risk SNPs and susceptibility regions
Lung cancer risk SNPs were extracted from the GWAS Catalog 11 and the literature search from PubMed (published before August 1, 2016 A gene was considered as lung cancer driver gene (CDG) if: (1) the gene is in the COSMIC Cancer Gene Census (v78) and is with evidence to be lung cancer related; 14 or (2) the gene was detected as lung cancer-related mutational-drivers, or somatic copy number alteration (SCNA)-drivers or fusion-drivers in the IntOGen database 15 or (3) the gene was identified as significantly mutated genes (SMGs) or candidate cancer driver genes with SCNAs by the TCGA LUAD and/or LUSC projects. 5 
Enrichment analysis of CDGs distribution in susceptibility regions
To evaluate whether the lung CDGs are more likely to locate in susceptibility regions, we firstly calculated proportion of CDGs in susceptibility regions. To estimate the background distribution of CDGs, we performed a random sampling of SNP sets throughout the genome. A total of 10,000 sets of SNPs with similar genetic properties as the susceptibility SNPs were randomly sampled by the SNPsnap Web server (https://data.broadinstitute.org/mpg/snpsnap/index.html), on which random SNPs are matched based on minor allele frequency, number of SNPs in LD (LD buddies), distance to nearest gene and number of nearby genes (gene density). 16 Random SNPs were analyzed with the same pipeline to construct a background proportion. p-Values for enrichment of CDGs in susceptibility regions were defined as follows:
Where N prop0 prop1 denotes the number of random SNP sets with proportions of CDGs equal or larger than that of lung cancer risk SNPs.
What's new?
Emerging evidence indicates that germline variations may interact with somatic events in carcinogenesis. However, germlinesomatic interactions in lung cancer largely remain unknown. Here, the authors investigated whether lung cancer driver genes (CDGs) were more likely to locate within cancer susceptibility regions. They found that CDGs were enriched in cancer susceptibility regions. Lung cancer susceptibility genes and CDGs were both enriched in nine pathways. Further analysis associated risk SNPs with somatic mutations at the level of genes, pathways, and APOBEC mutagenesis. These results indicate germlinesomatic interactions in lung tumorigenesis, and help to uncover the molecular mechanisms underlying lung cancer risk SNPs.
To investigate whether the extent of enrichment was influenced by length of flanking regions around susceptibility loci, we adopted different criteria to define susceptibility regions (i.e., 50 kb, 100 kb and 500 kb upstream and downstream of risk SNPs) in this analysis.
Pathway analysis
We downloaded KEGG pathways from the MSigDB website (http://software.broadinstitute.org/gsea/index.jsp) on 20/09/ 2016 and used the annotated gene symbols to perform our analysis. 17 The enrichment of CSGs or CDGs in a given pathway was tested using "PHYPER" function as implemented in R, which computes a p-values for each pathway based on hypergeometric distribution. We used BenjaminiHochberg correction to adjust for multiple hypotheses testing. Pathways with FDR 0.1 were considered as significant.
Genotypes
We utilized data from TCGA LUAD and LUSC projects to model the association between germline risk SNPs and somatic alterations. 3, 4 Germline genotypes of lung ADC and lung SqCC generated using the Affymetrix Genome-Wide Human SNP Array 6.0 were applied and approved in February 2015. A total of 1,002 cases were included after standard quality control process. Next, we performed genotype imputation using SHAPIT 18 for pre-phasing and IMPUTE2 for imputation, which was based on the 1,000 Genomes Project Phase III integrated variant set release (across 2,504 samples). 19 We included 22 susceptibility SNPs with imputation info 0.5, minor allele frequency (MAF) 0.01 and HardyWeinberg equilibrium p-values 0.001 for association analysis.
Association analysis on somatic mutations within significantly mutated genes and somatic copy numbers in significant regions of amplification or deletion
Mutation Annotation Format derived from whole-exome sequencing, as well as output files of SNP6 copy number analysis (GISTIC2) were downloaded from the Broad Institute Genome Data Analysis Center (GDAC) Firehose portal (stamp analyses_2016_01_28). 20 We included significantly mutated genes (SMGs) identified by Campbell et al. 5 based on the TCGA LUAD and/or LUSC projects. For each patient, an SMG was considered mutated if one or more DNA mutations mapped to this gene. And we only considered genes with somatic mutations in at least 10 patients. In the analysis of SCNAs, copy numbers of genomic regions with significant amplification or deletion were used as somatic phenotype.
Association analysis on somatic truncation mutations or copy number alterations within key pathways
For each patient, a pathway was considered as mutated if 1 or more truncation mutations (frame shift insertion/deletion, non-stop, stop-gained or splice site mutations) were observed in this pathway. When analyzing SCNAs, we only considered genes within regions of significant amplification or deletion. A gene was considered CNV altered if it received a GIS-TIC2.0 threshold score of 22 or 2 (recoded in all_threshol-ded.by_genes.txt). A pathway was defined to be CNV altered if 1 or more SCNAs occurred in this pathway. Pathways were Figure 1 . A flow chart of the study design. First, lung cancer risk SNPs and lung cancer driver genes (CDGs) were collected from published databases (published before August 1, 2016). Next, we performed an enrichment analysis to investigate whether lung CDGs are more likely to locate within susceptibility regions, and whether lung cancer susceptibility genes (CSGs) and CDGs are involved in shared biological pathways. In addition, we incorporated data from TCGA projects and analyzed the associations of lung cancer risk SNPs with somatic alterations in the level of genes, pathways, overall burden of somatic copy number variations, and APOBEC mutagenesis. Germline genotypes generated using the Affymetrix Genome-Wide Human SNP Array 6.0 were applied and approved in February 2015. Data of somatic alterations were downloaded from the Broad Institute Genome Data Analysis Center (GDAC) Firehose portal (stamp analyses_2016_01_28). LUAD: lung adenocarcinoma; LUSC: lung squamous cell carcinoma; SMG: significantly mutated genes; SCNA: somatic copy number alteration; WES: whole exome sequencing.
included if they (1) showed enrichment for lung CDGs, and (2) were recurrently altered in lung cancer. 21 As a result, cell cycle, MAPK signaling pathway, mTOR signaling pathway and spliceosome were included. In addition, we also included pathway of non-small cell lung cancer for association analysis.
Association analysis on APOBEC mutagenesis and burden of SCNAs APOBEC-signature mutations for TCGA lung patients were downloaded from the Broad Institute Genome Data Analysis Center (GDAC) Firehose portal (stamp analyses_ 2016_01_28). 20, 22 We used "tCw_to_G 1 tCw_to_T," which represents the total counts of APOBEC-signature mutations, in the downloaded file "*_sorted_sum_all_fisher_Pcorr.txt." The total counts of APOBEC-signature mutations were then log10 transformed as outcome. SCNAs with "log2() 21 of copy number" above 0.1 (or blow 20.1) were considered as amplifications (or deletions). The total length of amplification plus deletion segments across the genome was calculated (denoted as SCNAs burden) and quantile normalized for analysis.
Statistical analyses
To assess the associations between lung cancer risk SNPs and somatic alterations, logistic regression was used for binary phenotypes and multiple linear regression for quantitative traits. We used additive model and controlled for age, gender, smoking status, clinical stage and the first 10 principal components. Missing rates for all clinical variables were blow 5%, and we imputed missing clinical variable values using median value. Analysis was performed in lung ADC and lung SqCC separately, after which we conducted fixed effects metaanalysis using the inverse variance weighting. Also, we generated the index of heterogeneity (I 2 ) and p-values of Cochran's Q statistic to asses heterogeneity in meta-analyses and only considered associations showing little evidence for heterogeneity (p-values of Cochran's Q statistic >0.05). A false discovery rate (FDR) of 0.1 was used as significance threshold and all tests were two-sided. All analyses were conducted using R 3.1.3.
Results
We identified 29 lung cancer risk SNPs, among which 9 SNPs were reported in Europeans, 19 SNPs were reported in Asians, and 1 SNP was reported in both Europeans and Asians (Supporting Information Table S1 ). Based on the COSMIC Cancer Gene Census, IntOGen database and TCGA LUAD/LUSC projects, we included 348 CDGs (Supporting Information Table S2 ). Enrichment analysis showed that 6 out of 130 protein coding genes (5%) in lung cancer susceptibility regions were lung CDGs (enrichment p 5 8.40 3 10
23
), which indicated that CDGs were significantly enriched in lung cancer susceptibility regions (Supporting Information  Table S3 , Fig. 2 ). Additional analysis suggested that the proportion of CDGs in susceptibility regions decreased and the enrichment p-values increased with increasing region sizes, when 50 kb, 100 kb, 500 kb upstream and downstream of risk SNPs were applied (Fig. 2 , Supporting Information Table  S3 ). To investigate whether CSGs and CDGs would be involved in shared biological pathways, we conducted pathway enrichment test. Both of lung CSGs and CDGs demonstrated significant enrichment in 9 pathways, including nonsmall cell lung cancer, pancreatic cancer, p53 signaling pathway, cell cycle, TGF-b signaling pathway, natural killer cell mediated cytotoxicity, endocytosis, viral myocarditis and spliceosome (Fig. 3 , Supporting Information Table S4 ).
Analysis of somatic mutations in SMGs identified one significant SNP-gene pair with FDR <0.1 when we metaanalyzed the associations in LUAD and LUSC cohorts (Supporting Information Table S5 ). The risk allele (T) of rs36600 (22q12.2) was associated with somatic mutations in ARID1A (OR 5 2.45, 95%CI: 1.47-4.08, p 5 5.78 3 10 24 in meta-analysis). We also identified one SNP-gene pair with FDR <0.5: Information Tables S6 and S7 ). We also investigated the associations between risk SNPs and somatic copy numbers in significant regions of amplification and deletion, but did not find any association with FDR < 0.1 (Supporting Information  Tables S8 and S9 ). ) (Fig. 4 , Supporting Information Table S10 ). In the analysis of copy number alterations within key pathways, there were no significant interactions (Supporting Information Table S11 ).
SCNAs affect a larger fraction of the cancer genome compared to any other somatic alterations. 23 Information Fig. S1 , Table  S12 ), but such association was not detected in lung SqCC.
Somatic APOBEC mutational signatures of C > G or C > T changes at TCT or TCA motifs have been described in lung ADC and lung SqCC. 5, 24 We analyzed the association between risk SNPs and the total counts of APOBECsignature mutations. Only rs2395185 was significantly associated with APOBEC mutagenesis (effect allele: T, OR 5 1.08, 95%CI: 1.02-1.13, p 5 3.58 3 10 23 ) (Fig. 5 , Supporting Information Table S13 ). As APOBEC-signature mutations are generated by cytidine deaminases of APOBEC family, 25 we assessed the effect of mRNA expression of APOBECs on APOBEC mutagenesis in TCGA lung tumors. Increased expression of APOBEC3A and APOBEC3B were independently associated with higher APOBEC mutagenesis, while expression of APOBEC3C and APOBEC4 were independent predictors of decreased APOBEC mutagenesis (Supporting Information Fig. S2 ). Thus we further investigated whether the genotype of rs2395185 was associated with altered APOBECs expression. Based on the GTEx database (v6p release), we found that rs2395185 was associated with increased expression of APOBEC3A (effect allele: T, b coefficient 5 0.15, p 5 9.50 3 10 
Discussion
Somatic mutations emerge on the background of germline variants, some of which are associated with altered predisposition to cancer. In our study, we found that CDGs were more likely to locate within cancer susceptibility regions. A recent study explored somatic mutation profiles within susceptibility regions in a range of cancers, but found that genes in cancer susceptibility regions did not exhibit an overall increase in mutation frequency. 26 The published analysis considered overall somatic mutations, which consisted a substantial proportion of passenger mutations, while we focused on somatic alterations in CDGs. The enrichment of lung CDGs in lung cancer susceptibility regions indicated that specific germline variant could possibly modify the effect of nearby somatic alterations. As observed in bladder cancers, a common polymorphism rs2853669 in the TERT promoter could weaken the effect of somatic TERT promoter mutations. Patients who carried somatic lesions in the TERT promoter showed better survival in the presence but not in the absence of this germline SNP. 27 Pathway analysis showed that lung CSGs and CDGs were involved in 9 common pathways, the majority of which have been implicated in carcinogenesis (such as cell cycle, p53 signaling pathway and spliceosome). 21 These results suggested that risk SNPs could modulate the biological effects of somatic alterations through altered signaling transduction.
The interaction analysis of risk SNPs and somatic mutations in SMGs showed that the risk allele of rs36600 was significantly associated with ARID1A mutations. rs36600 was located within intron of MTMR3 and could regulate expression levels of MTMR3 in multiple normal tissues such as brain and thyroid (based on the GTEx database).
12
MTMR3 together with PIKfyve can regulate cancer cell migration and invasion by constituting a phosphoinositide loop that produces PtdIns5P on cellular membranes, which may then serve to recruit effectors to activate the Rho family GTPase Rac1. 28, 29 Interestingly, Rac 1 and its partner Unkempt was involved in the ubiquitination of BAF60b, which is thought to bridge interactions between transcription factors and SWI/SNF complexes. 30 ARID1A is also a member of the SWI/SNF chromatin remodeling complexes and has been demonstrated to have tumor suppression roles. 31 Thus, we speculate that rs36600 (MTMR3) might interact with ARID1A via shared biological processes.
To improve statistical power, we further conducted a pathway-based analysis. The risk allele of rs3817963 was associated with the occurrence of truncation mutations in cell cycle and MAPK signaling pathway. SNP rs3817963 is an intronic variant in BTNL2, and was identified as a risk SNP of lung ADC in Japanese. 32 Recently, rs3817963 was found to have stronger effect in EGFR mutated lung ADCs than in EGFR wide-type lung ADCs. 10 Consistently, we validated the association between rs3817963 and EGFR mutation in TCGA lung ADC with borderline significance (effect allele: C, OR 5 1.45, p 5 7.6 3 10
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, Supporting Information Table S6 ).
Interestingly, rs3817963 was also associated with truncation mutations in the MAPK signaling pathway, which includes EGFR gene. However, further studies are warranted to uncover the biological mechanism underlying these associations. In addition to truncation mutations in key pathways, genetic variants could also modulate overall patterns of somatic mutations. Carriers of the rs2395185-T allele have increased lung cancer risk, 33 and we suggest that this could partly be attributed to its association with increased APO-BEC3A expression and generation of APOBEC-signature mutations in lung tissues. The AID/APOBEC family of cytosine deaminase, which was identified as antiviral factors, can introduce mutations in single stranded DNA by converting cytosine to uracil, and are implicated in carcinogenesis. 25, 34 Both APOBEC3A and APOBEC3B have been proposed to cause APOBEC mutagenesis. 35, 36 Further analysis showed that rs2395185-related lung cancer susceptibility genes were enriched in pathways such as interferon signaling and immune system (Supporting Information Table S14 ). Studies demonstrated that APOBEC3A and APOBEC3B expression can be induced by interferons in response to viral infection (e.g., HBV and HPV). 37, 38 Also in breast tumors, germline APO-BEC3B deletion has been associated with increased immune response. 39 Therefore, rs2395185 might modulate APOBEC mutagenesis through its regulation of immune response. To summarize, our study investigated the interactions between risk SNPs and somatic alterations in lung cancer. We found that lung CDGs are more likely to locate within cancer susceptibility regions, and both of lung CSGs and CDGs showed significant enrichment in pathways such as cell cycle, non-small cell lung cancer and p53 signaling pathway. SNP-SMG interaction analysis showed that rs36600 was associated with somatic mutations within ARID1A. Pathwaybased analysis identified significant associations between rs2395185 and truncation mutations in cell cycle pathway, as well as associations of rs3817963 with truncation mutations in cell cycle and MAPK signaling pathway. We also found that rs2395185 was associated with increased APOBEC3A expression and elevated APOBEC mutagenesis. The interactions between risk SNPs and somatic alterations can help to uncover the molecular mechanisms by which risk SNPs influence cancer risk. However, the mechanisms with regard to how risk SNPs and somatic alterations interacted remain unclear. And functional experiments are warranted to uncover these mechanisms.
